ArticleRespiratory research2019
Predictive value of a series of inflammatory markers in COPD for lung cancer diagnosis: a case-control study.
Article in Respiratory research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 19 citations in OpenAlex.
- Efficacy of Xiyanping in the Treatment of Elderly Patients with Chronic Obstructive Pulmonary Disease and Its Effect on the Expression of GDF-15 and HIF-1Computational and mathematical methods in medicine · 2022Trial
- Novel biomarkers for lung cancer diagnosis in chronic obstructive pulmonary disease: a systematic review and metanalysis.Discover oncology · 2026Article
- The role of neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) in the early diagnosis of pulmonary mucoepidermoid carcinoma and their clinical significance.Journal of medical biochemistry · 2026Article
- The association between systemic immune-inflammation index and mortality of elderly chronic bronchitis patients complicated by acute myocardial infarction.Frontiers in cardiovascular medicine · 2026Article
- Predicting Lung Cancer Survival to the Future: Population-Based Cancer Survival Modeling Study.JMIR public health and surveillance · 2024Article
- The Diagnostic Value of Systemic Immune-Inflammatory Index (SII) and Lymphocyte-Albumin-Neutrophil Ratio (LANR) in Chronic Obstructive Pulmonary Disease with Lung Cancer.Journal of inflammation research · 2024Article
- Screening of Lipid Metabolism-Related Genes as Diagnostic Indicators in Chronic Obstructive Pulmonary Disease.International journal of chronic obstructive pulmonary disease · 2023Article
- Plasma Proteomics Enable Differentiation of Lung Adenocarcinoma from Chronic Obstructive Pulmonary Disease (COPD).International journal of molecular sciences · 2022Article
- Molecular and Clinicopathological Characteristics of Lung Cancer Concomitant Chronic Obstructive Pulmonary Disease (COPD).International journal of chronic obstructive pulmonary disease · 2022Article
- Diagnostic Accuracy of Liquid Biomarkers in Airway Diseases: Toward Point-of-Care Applications.Frontiers in medicine · 2022Review
- Blood monocyte counts as a prognostic biomarker and predictor in Chinese patients with idiopathic pulmonary fibrosis.Frontiers in medicine · 2022Article
- From Oxidative Stress to Inflammation in the Posterior Ocular Diseases: Diagnosis and Treatment.Pharmaceutics · 2021Review
- Alpha-1 antitrypsin deficiency and risk of lung cancer: A systematic review.Translational oncology · 2021Article
- Potential of Stem Cells and CART as a Potential Polytherapy for Small Cell Lung Cancer.Frontiers in cell and developmental biology · 2021Review
- Are elevated plasma fibrinogen associated with lung function? An 8-year follow-up of the ELSA study.PloS one · 2021Article
- CircRNA0001859, a new diagnostic and prognostic biomarkers for COPD and AECOPD.BMC pulmonary medicine · 2020Article
- LncRNA XIST Inhibits the Progression of Oral Squamous Cell Carcinoma via Sponging miR-455-3p/BTG2 Axis.OncoTargets and therapy · 2020Article
- CXCL9 as a Prognostic Inflammatory Marker in Early-Stage Lung Adenocarcinoma Patients.Frontiers in oncology · 2020Article
- Tubulin Alpha-1b as a Potential Biomarker for Lung Adenocarcinoma Diagnosis and Prognosis.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundThere is a relationship between Chronic Obstructive Pulmonary Disease (COPD) and the development of lung cancer (LC). The aim of this study is to analyse several blood markers and compare their concentrations in patients with only COPD and LC + COPD.
methodsCase-control study with cases presenting combined LC and COPD and two control groups (patients presenting only COPD and patients presenting only LC). We also included LC patients with descriptive purposes. In both groups, peripheral blood analyses of TNF-α, IL-6, IL-8, total leukocyte, lymphocyte and neutrophil counts, neutrophil-to-lymphocyte ratio, total platelet count, mean platelet volume, platelet-to-lymphocyte ratio, alpha 1-antitripsin (A1AT), IgE, C-reactive protein, fibrinogen, cholesterol and bilirubin were performed. We developed univariate and multivariate analyses of these markers, as well as a risk score variable, and we evaluated its performance through ROC curves.
resultsWe included 280 patients, 109 cases (LC + COPD), 83 controls (COPD) and 88 LC without COPD. No differences were observed in the distribution by sex, age, BMI, smoking, occupational exposure, lung function, GOLD stage or comorbidity. Patients with LC + COPD had significantly higher levels of neutrophils [OR 1.00 (95%CI 1.00-1.00), p = 0.03] and A1AT [OR 1.02 (95%CI 1.01-1.03), p = 0.003] and lower cholesterol levels [OR 0.98 (95%CI 0.97-0.99), p = 0.009] than COPD controls. We developed a risk score variable combining neutrophils, A1AT and cholesterol, achieving a sensitivity of 80%, a negative predictive value of 90.7% and an area under the curve of 0.78 (95%CI 0.71-0.86).
conclusionsCOPD patients who also have LC have higher levels of neutrophils and A1AT and lower of cholesterol. These parameters could be potentially predicting biomarkers of LC in COPD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.